Introduction Lung cancer is the leading cause of cancerrelated death worldwide. The discovery of new biomarkers could aid early diagnosis and monitoring of recurrence following tumor resection. Methods We have prospectively collected serum from 97 lung cancer patients undergoing surgery with curative intent and compared their serum proteomes with those of 100 noncancer controls (59 disease-free and 41 with a range of nonmalignant lung conditions). We initially analyzed serum from 67 lung cancer patients and 73 noncancer control subjects by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry using immobilized metal affinity capture ProteinChip arrays and subsequently validated our findings with an independent analysis of 30 lung cancer patients and 27 noncancer subjects. Results The data from both experiments show many significant differences between the serum proteomes of lung cancer patients and nondiseased control subjects, and a number of these polypeptides have been identified.
Introduction
Lung cancer is the leading cause of cancer-related mortality [1] . The majority of cases present with advanced disease, and only 20% are potentially curable by surgical resection [2, 3] . Current methods of lung cancer detection in symptomatic individuals are based on expensive and labor-intensive clinical and radiological assessments. Current serum markers are insufficiently sensitive or specific for screening and diagnosis. The discovery and validation of new biomarkers to aid early diagnosis and surveillance after tumor resection is a priority. Surface-enhanced laser desorption/ionization time-offlight mass spectrometry (SELDI) is a biomarker discovery tool that has been used by many groups, including ourselves, to examine the serum proteome of a wide range of cancer types in comparison to noncancer controls, e.g., [4] [5] [6] [7] [8] [9] . SELDI uses a combination of retentate chromatography and matrix-assisted laser desorption/ionization (MALDI) mass spectrometry to generate "proteomic profiles". The peak intensities in these profiles are then analyzed for significant differences between patient cohorts and used to generate class prediction models to discriminate between the cancer and noncancer patients. Once the discriminatory peaks have been selected, the proteins responsible for the peaks can be purified, digested, and identified by online liquid chromatography electrospray tandem mass spectrometry (LC-MS/MS). Identification of the proteins responsible for discriminatory SELDI peaks may allow antibody-based assays to be developed to assay these potential biomarkers.
Several groups have used SELDI serum analysis to search for diagnostic markers for nonsmall cell lung cancer but most have compared cancer patients to nondiseased control subjects [8, [10] [11] [12] [13] . Han et al. have reported that SELDI can distinguish between patients with small cell lung cancer and patients with pneumonia [14] . Yildiz et al. included diseased controls matched across their multisite case-control MALDI analysis of 288 patient sera [15] ; however, the sensitivity and specificity of their class prediction model was lower than in the single-site studies utilizing nondiseased controls. MALDI profiling of serum has also been shown to be able to predict the sensitivity of advanced nonsmall cell lung cancer to epidermal growth factor receptor inhibitors [16] .
We have now used SELDI to analyze the samples collected in the first phase of a prospective serum collection aimed at characterizing the serum proteomes of patients with resectable nonsmall cell lung cancer, disease-free control subjects, and patients with nonmalignant lung conditions. The data show that similar proteomic differences are detected between the sera of nondiseased individuals and cancer patients as between nondiseased individuals and benign disease controls. This study shows that the use of appropriate controls in serum proteomics is essential to avoid false-positive results.
Experimental Procedures

Patients and Serum Preparation
In a study specifically designed to identify lung cancer-related biomarkers, patients referred to Birmingham Heartlands Hospital for surgical resection of lung cancer, patients with a suspicious lung mass, and patients without lung cancer were recruited between January 2005 and April 2008. Informed consent was obtained from all participants using a protocol approved by the local ethics committee. The study was approved by the National Cancer Research Network. Sera were obtained from 97 patients in whom lung cancer was ultimately confirmed histologically; these constitute the cohort of cancer patients (33 female, 64 male, mean age 65.9 years) including 48 squamous cell carcinoma, 35 adenocarcinoma, 14 other nonsmall cell carcinoma with a stage distribution of 54 in stage I, 14 in stage II, 25 in stage III, and four stage IV. The control group comprised 100 patients (39 female, 61 male, mean age 63.2 years) of which 13 suspected of having lung cancer preoperatively underwent surgery and had benign thoracic pathologies (carcinoid, hamartoma), ten who underwent surgery for end-stage lung conditions (interstitial lung disease, end-stage emphysema), and 20 who had surgery for pleura pulmonary sepsis. Fiftynine patients were recruited as nonpulmonary controls attending the same hospital for a range of routine blood tests. Patient information is summarized in Table 1 .
Venous blood was taken into standard collection tubes with clot activator and allowed to clot for 1-2 h prior to 20 min centrifugation at 3,000×g. The supernatant was aspirated and placed in six 200-μl aliquots prior to storage at −80°C. Each sample was given a unique identification number to mask the identity (patient/control) from the laboratory staff performing the SELDI analysis.
SELDI Analysis
Sera were analyzed in duplicate on Cu 2+ -loaded immobilized metal affinity capture (IMAC) ProteinChip arrays using a Protein Biological System IIc time-of-flight mass spectrometer equipped with an autoloader (BioRad). All samples were randomized with respect to position in the 96-well bioprocessors used to process the ProteinChip arrays. Sera were processed, spectra acquired, and peak intensities extracted exactly as previously described [6, 7] . Statistically significant differences in peak intensity between patient cohorts were identified by Wilcoxon test.
Peak Identification
Serum samples rich in the peak of interest were diluted fourfold with 9 M urea, 2% 3-[(3-cholamidotropyl) dimethylammonio]-1-prop-anesulphonate, 50 mM Tris/ HCl (pH 9.0), and applied to Q Ceramic HyperD F anion exchange resin (Pall). Proteins were eluted from the resin using buffers at decreasing pH (7, 5, 4 , and 3). The fraction containing the SELDI peak of interest was then subjected to C4 and/or C18 reverse-phase high-performance liquid chromatography (RP-HPLC) using 4.6×250 mm columns (Phenomenex) and 0-80% acetonitrile gradients in 0.1% trifluoroacetic acid. The HPLC fractions were analyzed by MALDI (accurate masses were obtained for many of the SELDI peaks by reading the SELDI chips in a PerkinElmer ProTOF 2000 orthogonal time-of-flight MALDI). Fractions containing peaks of interest were lyophilized and either dissolved in 3% formic acid for LC-MS/MS without trypsinization or loading buffer for sodium dodecyl sulfate polyacrylamide gel electrophoresis (12% NuPage gels with MES buffer, Invitrogen). Gel bands were excised, reduced, alkylated, and digested with sequencing grade trypsin (Promega) as described previously [6, 7, 17] . Peptides were analyzed by LC-MS/MS using a ThermoFinnigan LCQ Deca XP Plus Ion-Trap linked directly to LC Packings/ Dionex Ultimate nanobore HPLC system. MS/MS data were searched against a database of nonredundant human protein sequences extracted from IPI human database (version 3.23) using SEQUEST. Mass tolerances were ±1.5 Da for parent ions and 0.0 for MS/MS fragments. Data were filtered using Xcorr values of 1.5, 2, and 2.5 for singly, doubly, and triply charged parent ions, respectively, and only first hits were considered.
Results
Initial SELDI Survey SELDI profiles were obtained for serum samples from 67 lung cancer patients and 73 noncancer controls (29 of the controls had benign lung diseases as detailed in Table 1 ). Wilcoxon tests revealed 46 significant differences in peak intensity between the cancer patients and the noncancer controls (p<0.01). However, when the noncancer cohort was divided into patients with benign lung diseases or no lung disease, a different picture emerged: There were 62 significant differences between lung cancer patients and patients without lung disease but only four significant differences between lung cancer patients and patients with benign lung diseases (m/z 1,544, 1,573, 6,631, 14,070). There were also no significant differences between patients with early (stage I/II) and late stage (stage III/IV) disease and only one (m/z 5,367) between patients with adenocarcinoma and squamous cell carcinoma. As can be seen from the fold changes shown in Table 2 , many of the differences between the nondiseased controls and the diseased controls are similar to those between the nondiseased controls and the cancer patients. Upon subdividing the diseased controls, Wilcoxon tests revealed seven significant differences between the benign tumor cohort and the cancer cohort (m/z 3,531, 4,138, 5,920, 6,682, 6,691, 14,070, 88,100) but none between lung cancer and end-stage lung disease or pleuropulmonary sepsis (p<0.01).
Peak Identifications
We have purified and identified ten of the polypeptides underlying the SELDI peaks that differ significantly in intensity between nondiseased controls and lung cancer patients (Table 3) . Most of the data used in the identifica- 58.0 9/6 --
The table shows the composition of the patient cohorts in the "discovery" and "validation" experiments tions (MS/MS spectra and immunoSELDI) are presented in "Supplemental Information". Two of these peaks at m/z 6,431 and 6,631, we have previously identified as apolipoprotein C1 and N-terminally truncated apolipoprotein C1 [7] and the identities were confirmed by immunoSELDI. The protein producing a peak at m/z 14,690 was purified, digested, and identified by LC-MS/MS (two tryptic peptides, 18% sequence coverage) as lysozyme C. This was confirmed by immunoSELDI. A pair of peaks at m/z 13,880 and 14,070 copurified and were identified as transthyretin (five tryptic peptides giving 58% sequence coverage). The two peaks most likely correspond to the cysteinylated and glutathionylated transthyretin that have been described previously [18] . A peak with m/z 5,080 was purified and trypsinized, and LC-MS/MS identified a single fully tryptic peptide (K.A 81 LGISPFHEHAEVVFTANDSGPR 103 126 .E, located C-terminal to R 103 , giving a total of 94% sequence coverage of the 5,077.67 fragment of transthyretin. No peptides derived from transthyretin Nterminal to A 81 were detected. The identification was confirmed by immunoSELDI using a polyclonal transthyretin antibody. In patients with an elevated m/z 5,080 SELDI peak, the intensity of the intact transthyretin peaks was decreased, consistent with the former being a proteolytic fragment of the latter (Fig. 1) .
Two peaks with m/z 3,273 and 3,289 copurified by anion exchange/RP-HPLC and were identified from one fully for both peptides showing a common series of y-ions and b-ions that are different by the mass of a serine residue.
Validation SELDI Survey
Independent validation was performed on samples collected after the initial experiment outlined above was completed. Sera from 30 lung cancer patients and 27 noncancer controls (12 with benign lung diseases) were analyzed using identical procedures. We found 44 significant differences between lung cancer and noncancer (no-disease and benign lung disease) controls, 86 significant differences between lung cancer and nondiseased controls but no significant differences between lung cancer patients and patients with benign lung disease. Although we found significant systematic differences between the two SELDI datasets (data not shown), many of the significant differences between lung cancer patients and disease-free controls were common to both experiments: Of the 62 peaks with p<0.01 for cancer versus disease-free in experiment 1, 41 also had p<0.01 and changed in the same direction in experiment 2 with p<0.01. This demonstrates both that SELDI is sufficiently reproducible to detect proteomic differences between patient groups on separate occasions and that many of the same differences occur in independent sets of patients.
The intensities of three peaks that differ significantly between cancer patients and nondiseased controls in both SELDI experiments and that have been identified are shown in Fig. 3 . These data demonstrate that the changes detected in lung cancer and benign diseases are similar and can be detected reproducibly.
Discussion
The experiments presented here show a number of SELDI peaks that are significantly increased or decreased in intensity in the serum of lung cancer patients compared to nondisease controls, as reported previously by several groups [10] [11] [12] [13] . However, when the noncancer controls were considered as two distinct groups, those with and without benign lung diseases, the vast majority of differences were only seen in the nondisease controls. The differences between nondisease controls and benign disease controls samples resembled the differences between the nondisease controls and the lung cancer patients.
Nonmalignant disease controls have been included in a number of SELDI cancer biomarker studies and confounding effects have either not been reported (presumably because they were not investigated or found to be negligible) or have only partially obscured cancer specific effects, e.g., [19] [20] [21] . We now report that some benign conditions can mimic the effect of cancer, a significant finding when one considers that much of the SELDI-based biomarker discovery literature utilizes only healthy controls, potentially generating many false leads. Although based on a very small number of patients (Table 1) , some significant differences were seen between patients with benign tumors and those with lung cancer, and these might have clinical utility in making this distinction in the absence of confounding conditions. Few previous SELDI/MALDI serum profiling studies of lung cancer have identified the polypeptides underlying disease associated peaks. However, it is known that despite the retentate chromatography step and the selective detection of the low molecular weight proteome, most of the peaks in SELDI spectra of serum arise from abundant serum proteins and their breakdown products [22, 23] . Thus, it is not surprising that the polypeptides underlying SELDI peaks differing significantly in intensity between lung cancer patients and nondiseased controls are also abundant serum proteins or fragments thereof. The SELDI intensities of the protein fragments that we have identified are all increased by lung disease, most likely because they are present at increased concentrations [24, 25] , possibly due to altered proteolytic activity in these patients. Transthyretin, a thyroxine transporting protein synthesized predominantly in the liver, is a negative acute phase protein and decreases in the serum of patients with various cancers including ovarian [9, 26] , pancreatic [27] , and lung [28] . However, we now provide evidence that the decrease in intact transthyretin in patients with lung disease may be at least partially due to proteolytic degradation (Fig. 1) . We also found the SELDI intensity of intact and truncated forms of apolipoprotein C1 and lysozyme C to be decreased in the serum of lung cancer patients. Both proteins are unlikely to be emanating directly from tumors and are altered in a number of other conditions, e.g. [7, 29] . In our study, the proteomic changes may well reflect the host response to the tumor, and it is perhaps not surprising that these proteins lack tumor specificity although cancer-type specific variants of transthyretin have been reported, including cysteine modifications and truncations [27, 30] . Several of the protein cleavages and modifications that we find in both the cancer patients and patients with benign lung diseases have previously been proposed as potential tumor biomarkers [30] [31] [32] . Our work shows that these modifications of abundant serum proteins are also associated with benign lung disease although we cannot rule out that more in-depth peptidome profiling might be able to discriminate between the effects of lung cancer and other lung diseases.
In conclusion, our SELDI data show that proteomic changes can be detected in the serum of lung cancer patients, and we have identified a number of the proteins involved. These changes are not specific to lung cancer but can also arise from nonmalignant lung conditions and unfortunately are not likely to prove useful as cancer biomarkers. This demonstrates that it is essential to the design of future proteomic cancer biomarker studies, regardless of the proteomic methodology employed, to include appropriate control subjects with a range of nonmalignant conditions to ensure the specificity of any markers detected. Indeed, it should be considered that the recruitment of appropriate noncancer controls is as important as that of the cancer patients.
